Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.76 |
| ▸ | GSK3B | P49841 | 11/20 | 0.74 |
| ▸ | GSK3A | P49840 | 7/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.70 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.70 |
| ▸ | CDC25B | P30305 | 1/20 | 0.62 |
| ▸ | IGF1R | P08069 | 2/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL623103 | 1.00 | CDK2 (0.76) | CDK2PIK3CGGSK3BGSK3AMEN1 | |
| SCHEMBL13479541 | 0.87 | CDK2 (0.72) | CDK2PIK3CGGSK3BGSK3AMEN1 | |
| SCHEMBL21067321 | 0.86 | CDK2 (1.00) | CDK2PIK3CGGSK3BGSK3AMEN1 | |
| SCHEMBL1064039 | 0.86 | PIK3CG (1.00) | CDK2PIK3CGMEN1POLBBLM | |
| SCHEMBL1064036 | 0.86 | PIK3CG (1.00) | CDK2PIK3CGMEN1POLBBLM | |
| SCHEMBL4200323 | 0.86 | PIK3CG (1.00) | CDK2PIK3CGMEN1POLBBLM | |
| SCHEMBL10118546 | 0.85 | GSK3B (1.00) | CDK2GSK3BGSK3AMEN1POLB | |
| SCHEMBL622714 | 0.85 | GSK3B (0.76) | CDK2PIK3CGGSK3BGSK3AMEN1 | |
| SCHEMBL622715 | 0.85 | GSK3B (0.76) | CDK2PIK3CGGSK3BGSK3AMEN1 | |
| SCHEMBL15315396 | 0.85 | GSK3B (0.76) | CDK2PIK3CGGSK3BGSK3AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | CDK2 960/4885PIK3CG 3728/4885GSK3B 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.